Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
about
Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsDNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in S. cerevisiaeThe elements of life and medicinesAntitumor activity of new enantiopure pybox-ruthenium complexes.Cellular and cell-free studies of catalytic DNA cleavage by ruthenium polypyridyl complexes containing redox-active intercalating ligands.Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacyRuthenium-based chemotherapeutics: are they ready for prime time?Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Inhibition of cancer cell growth by ruthenium complexesIn vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Heteroleptic arene Ru(II) dipyrrinato complexes: DNA, protein binding and anti-cancer activity against the ACHN cancer cell line.Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity.Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.Cytotoxic triosmium carbonyl clusters: a structure-activity relationship study.Regression of lung cancer by hypoxia-sensitizing ruthenium polypyridyl complexes.Selective, cytotoxic organoruthenium(II) full-sandwich complexes: a structural, computational and in vitro biological study.X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity.Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups.Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(III) drug bound to holo-transferrin in simulated cancer cytosol.A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells.Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells.A novel ruthenium complex with xanthoxylin induces S-phase arrest and causes ERK1/2-mediated apoptosis in HepG2 cells through a p53-independent pathway.A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells.Synthesis, DNA Cleavage Activity, Cytotoxicity, Acetylcholinesterase Inhibition, and Acute Murine Toxicity of Redox-Active Ruthenium(II) Polypyridyl Complexes.The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.Kinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoleruthenate(iii)], NAMI-A, by 2-mercaptoethane sulfonate
P2860
Q26800031-233778E3-2175-4842-B09E-B91D552C4593Q28548049-C4C4E815-CAB3-4CA0-BB8D-533B82019397Q28649323-8588394B-E9F7-497E-B4C4-A0F87342204FQ30660221-B7071280-3A2C-4648-BA01-7EF3B31585D3Q33670035-4042ACD5-9383-4A8A-A4ED-17A1E05CF932Q33915894-1B34321B-AFA7-4C8B-A106-04954AD71FEFQ34102818-5E78871E-656B-4B64-B2EF-93F422B32A7DQ36253687-12583599-FF46-4A26-9831-89592C0E14E7Q36287265-82F82894-9DA8-424F-B7DB-805BB263AD10Q36574799-8EA2C3F7-61DD-4E6B-BEAD-2E0128C10EDAQ37263372-57B5984F-3AA9-4361-92EF-F85627B516BCQ37657640-D6551F63-AC06-48C5-9EFE-CD493469DFB1Q37997361-F92F7B69-346F-45D8-8C90-72816C8AEB90Q38052406-1DC44396-2499-4418-B0EF-FBD229DB5E8FQ38105454-413C1C3A-92FF-4ADF-9088-CE0ED6EF82C9Q38699445-A1F1F6D0-DBFA-4F25-B875-AEC08011C1FFQ38783737-058CEE94-1509-497D-BC71-9F73880B6DDDQ38941268-D5ADEAA0-B3C1-447D-AC9E-20BC9539BF03Q38995385-590B2E7D-92D2-4942-A673-A7EB914851F1Q39032502-E2B8AE66-BF04-4CBE-8F62-AB53AB3D1984Q39188111-DE5E9049-4CBB-47EA-B044-9EB8EAC9C129Q39440872-B62D5F75-9F0A-4285-9F23-306BE6DBDCADQ39753526-7ED13A8E-DEEC-494D-9A29-4532EA7AD5D5Q40759010-68072AE0-FE4B-48D1-AB6D-0A0038DC507CQ41642755-6841C134-A4AE-4238-B774-41499BC870E9Q42373851-DD356EDB-5EF0-406B-B40D-7CE26E49B119Q43451056-4AED096A-4178-4FE2-91B2-3E6AA252406EQ43811304-6E769599-D054-46E2-8BC8-3351040B83F6Q45968243-5B706C0D-B09A-4254-93AD-0223BD7CC323Q46750665-0D2DE869-6577-4D35-B592-C1A0F4215E40Q47128819-8246B835-294E-432E-B562-EA00E81B5292Q48181192-0E900227-B3D1-41D3-8EA2-8E65B5C32A8DQ48267257-55CD32C0-5B78-408A-8077-EC1FBF265613Q48291622-093F4AE3-4D67-4672-B9EE-44D11E53BB3AQ49611544-B835EE3A-7848-4FA1-B02C-887E930F18E7Q49687144-CFEEF4C8-EB10-43F3-996C-E0046199A507Q50063144-4CB7EBD5-3AEA-41DB-97B2-924943E3BAB5Q59205403-7D59F9DF-FF7E-4B5A-87F5-371AC7EFC07F
P2860
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@ast
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@en
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@nl
type
label
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@ast
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@en
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@nl
prefLabel
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@ast
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@en
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@nl
P2093
P1433
P1476
Pharmacokinetics of a novel an ...... phase I dose-escalation study.
@en
P2093
Andreas Lindauer
Anne Drescher
Central European Society for Anticancer Drug Research-EWIV
Christian Dittrich
Frederike Lentz
Magdalena Henke
Max E Scheulen
Ralf A Hilger
Ulrich Jaehde
P304
P356
10.1097/CAD.0B013E328322FBC5
P577
2009-02-01T00:00:00Z